Study Details

Back
Study ID OSI-774-104
Study Title An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients with Advanced Solid Tumors with Adequate and Moderately Impaired Hepatic Function
Clinicaltrials.gov Identifier NCT00139620
Compound Name OSI-774 / erlotinib
Medical Indication or Disease Non-small cell lung cancer
Study Sponsor OSI Pharmaceuticals, Inc.
Collaborator Not Applicable
Study Start Date 22-Aug-2005
Study Completion Date 25-Jun-2007
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS